Paper Details

  1. Home
  2. Paper Details

Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review.

Author: ChenLizhang, DaiXiahong, FanXuegong, TangLanhua, ZhaoShushan, ZhouRongrong

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This article discusses the lack of conclusive results on the comparison of the efficacy of lamivudine (LAM) and telbivudine (LdT) in the treatment of chronic hepatitis B.
Paper Details　
Original Abstract of the Article :
Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as lamivudine and telbivudine, are recommended for treatment of patients with chronic hepatitis B. However, there are no conclusive results on the comparison of the efficacy of lamivudine (LAM) and telbi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939564/

データ提供：米国国立医学図書館（NLM）

A Comparative Study of Lamivudine and Telbivudine in Chronic Hepatitis B

Chronic hepatitis B, a persistent liver infection, is like a desert sandstorm, gradually eroding the liver's health. This systematic review explores the efficacy of lamivudine and telbivudine, two antiviral medications often used to treat chronic hepatitis B. The researchers, like diligent desert explorers seeking the most effective routes, systematically analyzed existing research to compare the effectiveness of these two drugs. Their findings provide valuable insights into the relative efficacy of these medications, helping physicians make informed treatment decisions for their patients.

Navigating the Desert of Hepatitis B Treatment

This systematic review, like a carefully crafted desert map, guides us through the complex landscape of hepatitis B treatment. The researchers meticulously analyzed existing research, comparing the effectiveness of lamivudine and telbivudine, two commonly used antiviral medications. Their findings provide valuable insights for physicians, helping them choose the most effective treatment for their patients, ensuring a safer and more successful journey through hepatitis B therapy.

Finding the Right Oasis in the Desert of Hepatitis B: Treatment Options

Chronic hepatitis B, like a persistent desert sandstorm, can pose significant health challenges. This systematic review offers valuable insights into the relative effectiveness of lamivudine and telbivudine, two antiviral medications commonly used to treat this condition. By understanding the strengths and limitations of each medication, physicians can make informed treatment decisions, guiding patients toward a healthier and more fulfilling life.

Dr. Camel's Conclusion

This systematic review, like a desert oasis, offers a comprehensive overview of the treatment options for chronic hepatitis B. The researchers' findings highlight the relative effectiveness of lamivudine and telbivudine, two commonly used antiviral medications. By understanding the nuances of these treatments, physicians can make informed decisions, guiding patients towards a healthier and more fulfilling journey through hepatitis B therapy.

Date :
  1. Date Completed 2010-12-01
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20815890

DOI: Digital Object Identifier

PMC2939564

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.